You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Excessive polypharmacy and survival in polypathological patients
|
|---|---|
| Published in |
European Journal of Clinical Pharmacology, April 2015
|
| DOI | 10.1007/s00228-015-1837-8 |
| Pubmed ID | |
| Authors |
Jesús Díez-Manglano, Mercedes Giménez-López, Vanesa Garcés-Horna, María Sevil-Puras, Elena Castellar-Otín, Paloma González-García, Isabel Fiteni-Mera, Teresa Morlanes-Navarro, on behalf of the PLUPAR Study Researchers |
| Abstract |
The purpose of this study was to determine whether excessive polypharmacy is associated with a higher survival rate in polypathological patients. An observational, prospective, and multicenter study was carried out on those polypathological patients admitted to the internal medicine and acute geriatrics departments between March 1 and June 30, 2011. For each patient, data concerning age, sex, comorbidity, Barthel and Lawton-Brody indexes, Pfeiffer's questionnaire, socio-familial Gijon scale, delirium, number of drugs, and number of admissions during the previous year were gathered, and the PROFUND index was calculated. Polypharmacy was defined as the use of ≥5 drugs and excessive polypharmacy as the use of ≥10. A 1-year long follow-up was carried out. A logistic regression model was performed to analyze the association of variables with excessive polypharmacy and a Cox proportional hazard model to determine the association between polypharmacy and survival. We included 457 polypathological patients. Mean age was 81.0 (8.8) years and 54.5 % were women. The mean number of drugs used was 8.2 (3.4). Excessive polypharmacy was directly associated with heart disease [hazard ratio (HR) 2.33 95 % CI 1.40-3.87; p = 0.001], respiratory disease [HR 1.87 95 % CI 1.13-3.09; p = 0.01], peripheral artery disease/diabetes with retinopathy and/or neuropathy [HR 2.02 95 % CI 1.17-3.50; p = 0.01], and the number of admissions during the previous year [HR 1.21 96 %CI 1.01-1.44; p = 0.04]. It was inversely associated with delirium [HR 0.48 95 % CI 0.25-0.91; p = 0.02]. There were no statistical differences regarding the probability of 1-year survival between patients with no polypharmacy, with simple polypharmacy, and with excessive polypharmacy (0.66, 0.60, and 0.57, respectively, p = 0.12). A greater use of drugs may not be harmful but is also not associated with a higher probability of survival in polypathological patients. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 25% |
| United Kingdom | 2 | 17% |
| Canada | 1 | 8% |
| Australia | 1 | 8% |
| United States | 1 | 8% |
| Unknown | 4 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 67% |
| Practitioners (doctors, other healthcare professionals) | 2 | 17% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
| Scientists | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 95 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 95 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 12% |
| Researcher | 10 | 11% |
| Student > Master | 10 | 11% |
| Student > Ph. D. Student | 9 | 9% |
| Student > Doctoral Student | 8 | 8% |
| Other | 25 | 26% |
| Unknown | 22 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 35 | 37% |
| Nursing and Health Professions | 12 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 11% |
| Mathematics | 2 | 2% |
| Business, Management and Accounting | 1 | 1% |
| Other | 6 | 6% |
| Unknown | 29 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2016.
All research outputs
#3,175,909
of 22,800,560 outputs
Outputs from European Journal of Clinical Pharmacology
#252
of 2,557 outputs
Outputs of similar age
#43,449
of 265,108 outputs
Outputs of similar age from European Journal of Clinical Pharmacology
#7
of 27 outputs
Altmetric has tracked 22,800,560 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,557 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,108 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.